Two classes of ER inhibitors are currently approved for breast cancer treatment, selective estrogen receptor modulators (SERMs), exemplified by tamoxifen and raloxifene, and selective estrogen receptor downregulators (SERDs), such as fulvestrant and ICI-164384. The gene discussed is ESR1; the disease is breast carcinoma.